Asahi Kasei Group, a global Japanese chemical company, offered to acquire Veloxis, a Danish pharmaceutical company, for $1.3bn. The offer price represents a premium of 6% compared to the 30-trading day volume weighted average share price of the target. "Veloxis has created signicant value for all shareholders which we believe is reflected in this tender offer. We are excited about the commitment Asahi Kasei has made to the continued development of Veloxis while also maintaining the Company’s focus on improving the lives of transplant patients," Michael Heffernan, Veloxis Chairman of the Board of Directors.